Final Report Summary - 3DNSBT (Three-dimensional nanofiber scaffolds as a model for the study of brain tumour migration)
3DNSBT- Final report. Sean Lawler
3DNSBT only completed year 1, as the applicant moved outside the EU. The aim of the study was to use a novel cell migration assay based on electrospun biocompatible nanofibers made of polycaprolactone to understand further mechanisms of cell migration in glioblastoma.
Significant Results
Significant results are as follows:
1. Assessment of cell migration in nanofiber assays. Poster is attached to the year 1 report. A paper is currently in preparation for submission to a peer-reviewed journal in which nanofiber migration assays were used to characterize migratory behavior in a panel of paediatric glioblastoma cell lines.
2. We have obtained full ethical approval to begin a brain tumour bank at Leeds. Patient consent, anonymisation, and sample transit and storage were all features of the plan.
3. We have obtained microarray data (gene expression and microRNA) from glioblastoma cells migrating in the presence and absence of indirubin or lithium as anti-migratory treatments. There was not time available during the funding period to analyze this data fully, however, it has many interesting candidates that will be examined in the future. All EU funded future work will be acknowledged.
4. Optimization of transfection and assay conditions in preparation for a robotic high throughput screen on nanofibers.
3DNSBT only completed year 1, as the applicant moved outside the EU. The aim of the study was to use a novel cell migration assay based on electrospun biocompatible nanofibers made of polycaprolactone to understand further mechanisms of cell migration in glioblastoma.
Significant Results
Significant results are as follows:
1. Assessment of cell migration in nanofiber assays. Poster is attached to the year 1 report. A paper is currently in preparation for submission to a peer-reviewed journal in which nanofiber migration assays were used to characterize migratory behavior in a panel of paediatric glioblastoma cell lines.
2. We have obtained full ethical approval to begin a brain tumour bank at Leeds. Patient consent, anonymisation, and sample transit and storage were all features of the plan.
3. We have obtained microarray data (gene expression and microRNA) from glioblastoma cells migrating in the presence and absence of indirubin or lithium as anti-migratory treatments. There was not time available during the funding period to analyze this data fully, however, it has many interesting candidates that will be examined in the future. All EU funded future work will be acknowledged.
4. Optimization of transfection and assay conditions in preparation for a robotic high throughput screen on nanofibers.